PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Foamix Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Foamix Granted Comprehensive US Patent for PerFoam® - Ideal Foam Treatment for Head Lice and Scabies - Foamix Ltd, a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office
Foamix Granted Comprehensive US Patent for PerFoam® - Ideal Foam Treatment for Head Lice and Scabies

 

NewswireToday - /newswire/ - Rehovot, Israel, 2012/03/13 - Foamix Ltd, a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

US Patent No. 8,119, 150, entitled “Non-flammable insecticide composition and uses thereof” relates to Foamix’s novel safe and effective insecticide compositions, suitable for treating insect infestations.

Foamix’s Permethrin 1% foam (“PerFoam® One”) was developed for the treatment of head lice. It was tested clinically in 56 children, infested with head lice; and demonstrated a 96% efficacy rate, with no side effects. From the usability point of view, PerFoam® One is superior. It is easy to apply, allows precise application without spreading on clothes or other parts of the body, and no protection of the eyes is required.

PerFoam® Five, Foamix’s Permethrin 5% foam is directed for the treatment of scabies. While anti-scabies creams require extensive rubbing throughout the whole body surface, foam makes treatment easy. The Foamix foam spreads readily on large skin areas and absorbs quickly.
This invention further relates to a variety of insecticide compounds that can be incorporated in foam to create best-in-class medications for parasite therapy.
"The grant of our PerFoam® patent in the US broadens our intellectual property portfolio," said Dr. Dov Tamarkin, CEO of Foamix. “We will now be able to imply our superior foam platforms and technologies into a patent protected product for treating head lice and scabies."

About Head Lice
The Centers for Disease Control and Prevention (CDC) (2010) reports an estimated 6 million to 12 million infestations occur each year in the United States among children 3 to 11 years of age. Girls are at greater risk because they have more frequent head-to-head contact. Head lice affect people across the socioeconomic spectrum.

About PerFoam® One
Foamix’s PerFoam® One, comprised of 1% Permethrin and two proprietary enhancers, is an alcohol-free, non-irritating, drip-free foam for the treatment of head lice. A clinical study entitled “An open study to assess the efficacy, safety and usability of a 1% Permethrin Foam, in the treatment of head lice (pediculosis capitis) in pediatric patients” was conducted at the Laniado Medical Center, Israel. Fifty-six children, aged 3-16, infested with head lice, were treated with PerFoam® One. The foam was applied to the hair for 10 minutes and then washed. Treatment was repeated 10 days later. PerFoam® One proved effective in killing the lice on the first application in 54 of the 56 children (96.4%). Furthermore, in 60% of the children, lice eggs were completely eradicated after the first application. The product was easily applied and caused no discomfort to the treated children. There was no evidence of eye or skin irritation.

About Scabies
Scabies is one of the three most common skin disorders in children.1 The mites are distributed around the world and equally infect all ages, races, and socioeconomic classes in different climates. Over 300 million people are affected by scabies worldwide, with millions of infections in the U.S. alone.2 People of all ages, genders, races, and social classes get scabies; and they easily spread within families, to sexual partners, and among people living in crowded conditions.

A number of medications is effective in treating scabies; however treatment must often involve the entire household or community to prevent re-infection.

Permethrin is the most effective treatment for scabies, and the treatment of choice. It is applied from the neck down usually before bedtime and left on for about 8 to 14 hours. Foam is an ideal carrier for scabies medications, as it spreads easily on large skin areas and absorbs quickly.
1 Pediatr Clin North Am. 2009 Dec;56(6):1421-40.
2 Lancet. 2000;355:819–826.

About PerFoam® Five
Foamix’s PerFoam® Five is an emollient formulation of Permethrin, ideal for the treatment of scabies and severe cased of pediculosis. It spreads easily on large skin areas and absorbs immediately upon application, and thus is expected to provide significant advantage to patients, in comparison to the traditional creams which require extensive rubbing in order to attain adequate spreading and absorption.

About Foamix
Foamix Ltd (foamix.co.il) is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.

The Company’s development capabilities range from initial development of the formulations and analytical methods to scale-up, GMP manufacturing, preclinical and clinical studies.

Foamix has a strong in-house pipeline. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 13 issued patents in the United States, covering its foam and OilGel™ technology platforms. Additionally, the company has more than 140 patents and patent applications worldwide, of which about 60 applications are filed in the U.S.

Contacts:
Dorit Hayon, Business Development Manager, Foamix Ltd, dorit[.]foamix.co.il
Dov Tamarkin, CEO, Foamix Ltd, dov[.]foamix.co.il.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Foamix Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Foamix Granted Comprehensive US Patent for PerFoam® - Ideal Foam Treatment for Head Lice and Scabies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Foamix Ltd |
Publisher Contact: Dorit Hayon - Foamix.co.il 
+972 89316233
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Foamix Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Foamix Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)